Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

CANbridge Makes Dismal Hong Kong Debut, but Raises $77.46M

Published 12/09/2021, 11:59 PM
Updated 12/10/2021, 12:03 AM
© Reuters.

© Reuters.

By Gina Lee

Investing.com – Canbridge Pharmaceuticals Inc. (HK:1228) made a dismal debut in Hong Kong that raised around HK$604 million ($77.46 million).

Shares were at HK$9.07 by 11:57 PM (4:57 AM GMT). The biopharmaceutical company issued 56,251,000 shares globally at a final offer price of HK$12.18 per share.

Morgan Stanley (NYSE:MS) Asia Limited and Jefferies (NYSE:JEF) Hong Kong Limited were the offering’s joint sponsors, while RA Capital, Hudson (NYSE:HUD) Bay Master Fund Ltd, Janus Investors, General Atlantic, WuXi Biologics, Ruihua Capital and Belinda A. Termeer were the seven cornerstone investors.

Founded in 2012, CANbridge develops products and product candidates targeting prevalent rare diseases and rare oncology indications, including glioblastoma multiforme (GBM) and mucopolysaccharidosis type II (MPS II or Hunter syndrome). Its pipeline of 13 drug assets includes three marketed products, four drug candidates at the clinical stage, one at the IND-enabling stage, two at the pre-clinical stage, and three gene therapy programs at the lead identification stage.

The company’s core product is CAN-008, a glycosylated CD95-Fc fusion protein to treat GBM. It received approval for a first-line phase II trial in China for GBM in April 2021 and dosed the first patient in October 2021. The Company targets commercializing CAN-008 in China as a combination therapy with radiotherapy plus chemotherapy, currently the standard of care for GBM patients.

China’s National Medical Products Association also gave investigational new drug approval for CAN-106, a humanized monoclonal antibody targeting complement C5 treating complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH), in July 2021.

Meanwhile, two other companies made mixed Hong Kong debuts on Friday. Shares in Chinese contract drug manufacturer Asymchem Laboratories Tianjin Co. Ltd. (HK:6821) were at HK$373.6, after falling as low as HK$369.2. However, the largest IPO in the city since Dongguan Rural Commercial Bank Co. Ltd.'s (HK:9889) $1.2 billion deal in September 2021 raised around HK$7.15 billion ($916.97 million).

Shares in traditional Chinese medicine healthcare service provider Gushengtang Holdings Ltd. (HK:2273) were at HK$29, after jumping as much as 18% in a $104 million listing.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.